Mohit Rawat

Mohit Rawat is the Boston-based CEO of Myricx Bio, a UK-US biotech building a first-in-class antibody-drug conjugate platform based on NMT inhibition to treat cancer. He arrived in September 2025 fresh off Fusion Pharmaceuticals' $2.4 billion sale to AstraZeneca, where he was President and Chief Business Officer. With a Harvard MBA, an MIT chemical engineering master's, and stints at Novartis, AbbVie and McKinsey, he is steering Myricx toward its first human clinical trials in 2026.